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Background: Intra-abdominal hypertension (IAH) and abdominal compartment syndrome (ACS) have detrimental
effects on all organ systems and are associated with increased morbidity and mortality in critically ill patients
admitted to an intensive care unit. Intra-bladder measurement of the intra-abdominal pressure (IAP) is currently the
gold standard. However, IAH is not always indicative of intestinal ischemia, which is an early and rapidly developing
complication. Sensitive biomarkers for intestinal ischemia are needed to be able to intervene before damage becomes
irreversible. Gut wall integrity loss, including epithelial cell disruption and tight junctions breakdown, is an early
event in intestinal damage. Intestinal Fatty Acid Binding Protein (I-FABP) is excreted in urine and blood specifically
from damaged intestinal epithelial cells. Claudin-3 is a specific protein which is excreted in urine following disruption of
intercellular tight junctions. This study aims to investigate if I-FABP and Claudin-3 can be used as a diagnostic tool for
identifying patients at risk for IAP-related complications.
Methods/Design: In a multicenter, prospective cohort study 200 adult patients admitted to the intensive care unit
with at least two risk factors for IAH as defined by the World Society of the Abdominal Compartment Syndrome
(WSACS) will be included. Patients in whom an intra-bladder IAP measurement is contra-indicated or impossible and
patients with inflammatory bowel diseases that may affect I-FABP levels will be excluded. The IAP will be measured
using an intra-bladder technique. During the subsequent 72 hours, the IAP measurement will be repeated every six
hours. At these time points, a urine and serum sample will be collected for measurement of I-FABP and Claudin-3
levels. Clinical outcome of patients during their stay at the intensive care unit will be monitored using the Sequential
Organ Failure Assessment (SOFA) score.
Discussion: Successful completion of this trial will provide evidence on the eventual role of the biomarkers I-FABP and
Claudin-3 in predicting the risk of IAP-associated adverse outcome. This may aid early (surgical) intervention.
Trial registration: The trial is registered at the Netherlands Trial Register (NTR4638).
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Patients undergoing major surgery or sustaining severe
trauma are at risk of developing morbidity and mortality
from postoperative or posttraumatic systemic inflamma-
tory response syndrome, sepsis and multiple organ dys-
function. The development of such potentially lethal
complications in otherwise healthy patients is poorly
understood. Data from a prospective multicenter epi-
demiological study showed that intra-abdominal hyper-
tension (IAH) is associated with increased morbidity and
mortality rates in critically ill patients admitted to an in-
tensive care unit (ICU) [1,2]. Therefore, early identifica-
tion of patients at risk for IAH-related morbidity and
mortality can be potentially lifesaving.
Intra-abdominal pressure and intra-abdominal hypertension
Compliance of the abdominal wall together with the ab-
dominal content determines the intra-abdominal pressure
(IAP) level. Under physiologic situations, the IAP level is
below 12 mmHg. Increased pressure in the abdomen is
known as intra-abdominal hypertension (IAH). This is
defined as a sustained IAP ≥12 mmHg [3]. IAH results
in reduced blood flow to most organs, with consequent
dysfunction of the cardiovascular, respiratory, renal, gastro-
intestinal, and central nervous systems. An IAP >20 mmHg
in combination with new organ dysfunction is indicative of
an abdominal compartment syndrome (ACS). The ultimate
treatment of ACS is a decompressive laparotomy. Risk fac-
tors for ACS include leakage of an aneurysm of the ab-
dominal aorta, closing the abdomen under pressure after
abdominal surgery, damage control laparotomy, hyper-
hydration during hypovolemic shock, pancreatitis, and
pulmonary contusion. These risk factors may apply to a
majority of patients in the ICU. The mortality risk in pa-
tients with ACS may be as high as 80% [1].
The current gold standard measurement tool as put for-
ward by the World Society of the Abdominal Compartment
Syndrome (WSACS; http://www.wsacs.org/education/
algorithms.html) is an intra-bladder pressure measure-
ment. This is a simple, minimally invasive method, and
the results are immediately available [3]. From a clinical
perspective, however, the IAP level does not always rep-
resent the presence of intestinal ischemia and as such is
not a perfect indicator for clinical outcome nor surgical
therapy. Sensitive biomarkers indicative of early (i.e., re-
versible) organ dysfunction are therefore needed as add-
itional diagnostic tool. The combination of increased
IAP and a biomarker level that represents organ damage
would support the need for and timing of decom-
pressive measures to relieve the abdominal pressure.
Biomarkers released upon loss of small intestinal integrity
Evidence is accumulating that the intestines play a cen-
tral role in the origin of postoperative and posttraumaticsequelae [4-6]. Enterocyte damage and tight junction
loss can be triggered by IAH, and both result in loss of
intestinal integrity. As a consequence, toxins, bacteria,
and undigested food particles may pass the enterocyte
layer, enter the underlying vasculature, and trigger systemic
inflammatory reactions that may progress to multiple organ
dysfunction syndrome and even death. Peptides released
upon enterocyte damage (e.g., Intestinal Fatty Acid Binding
protein; I-FABP) or tight junction loss (e.g., Claudin-3) are
potentially ideal biomarkers that will help identify patients
with early IAH-induced intestinal damage.
I-FABP is a small (14–15 kDa) protein that is exclusively
present in mature enterocytes of the small and large intes-
tine. It is released into the circulation upon enterocyte
membrane integrity loss and rapidly excreted into the
urine (half-life 11 minutes). Elevated I-FABP levels have
been found in plasma, serum, and urine in patients with
intestinal ischemia, celiac disease, systemic inflammatory
response syndrome and necrotizing enterocolitis [7-15].
I-FABP levels can be measured sensitively in plasma,
serum, and urine using an enzyme-linked immunosorb-
ent assay (ELISA) [7,8].
Claudins are small (22 kDa) tight junction proteins
[4,16-19]. Especially Claudin-3 is expressed in high quan-
tities solely in the intestine [18]. The amount of Claudin-3
in the intestine decreases after tight junction integrity loss
[17]. Breakdown of tight junctions by loss of Claudins (as
measured on Western blots in urine) is an early event in
intestinal damage, resulting in intestinal barrier loss [20].
The main aim of the current study is to investigate if
urinary levels of I-FABP can be used as a diagnostic tool for
identifying patients at risk for IAP-related complications.
Secondary aims are to determine the same for serum levels
of I-FABP and for urinary and serum levels of Claudin-3.
Methods/Design
Study design and setting
Multicenter prospective observational study of 200 patients
admitted to the ICU of Erasmus MC, University Medical
Center Rotterdam (Rotterdam, The Netherlands) or
Radboud University Medical Center Nijmegen (Nijmegen,
The Netherlands), who are at risk for developing IAH or
ACS according to the definitions of the World Society of
the Abdominal Compartment Syndrome [3]. Since it was
suggested that patients who have undergone liver trans-
plantation should also be screened for IAH [21,22], liver
transplantation has been added to the list of risk factors.
The study is registered at the Netherlands Trial Register
(NTR4638).
Study population and eligibility criteria
All adult patients admitted to the ICU who have at least
two risk factors for developing IAH or ACS according to
the WSACS will be eligible for inclusion [3].
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be eligible for enrolment:
1. Patients with at least two risk factors putting them
at risk for IAH or ACS as agreed by the WSACS.
Risk factors may be present already at admission,
but also patients developing risk factors during ICU
stay will be eligible from that moment onwards;
2. Age 18 or older, with no upper age limit;
3. Signed informed consent by patient or proxy.
If any of the following criteria applies, patients will be
excluded:
1. Patients in whom intra-bladder pressure measurement
is contra-indicated. This includes patients with bladder
trauma or hematuria;
2. Patients in whom intra-bladder pressure measurements
are not reliable due to intraperitoneal adhesions,
bladder oppressive pelvic hematoma, abdominal
packs in situ, (previous) bladder tumor or previous
bladder removal;
3. Patients with any inflammatory bowel disease that
may affect I-FABP levels.
Exclusion of a patient because of enrolment in another
ongoing drug or surgical intervention trial will be left to
the discretion of the attending surgeon on a case-by-case
basis.
Treatment
Patients with increased pressure determined by the intra-
bladder pressure measurements will be treated in com-
pliance with the algorithms for patient management as
developed by the WSACS (www.wsacs.org/algorithms.php)
[3]. The IAH Assessment Algorithm describes all risk fac-
tors that every patient should be screened for upon inten-
sive care unit admission and upon clinical deterioration
leading to new organ dysfunction. The intra-bladder pres-
sure will be measured in patients with two or more risk
factors for IAH or ACS or in patients who have under-
gone a liver transplantation. Patients who do not have two
or more risk factors at baseline but develop new risk fac-
tors during their ICU admission will be followed from that
moment onwards. The reason for this is that the occur-
rence of IAH during intensive care stay is known to be an
independent predictor for mortality, whereas presence of
IAH at intensive care admission is not [23]. Patients
should be enrolled as soon as possible, but at least within
48 hours after meeting the eligibility criteria. The IAH/
ACS Management Algorithm provides a decision tree for
the follow-up of patients related to the IAP level. The
IAH/ACS Medical Management Algorithm provides a
stepwise approach of actions to be taken for achievingIAP pressure relief. In short, ICU management will be
provided by the attending physicians and may consist of,
among others, balanced intravenous fluid administration,
correction of hypovolemia, electrolyte disturbances and/or
anemia and analgesics.
Outcome measures
I-FABP levels will serve as primary outcome measure.
Urinary and serum concentrations of I-FABP will be ana-
lyzed in duplicate using a highly specific, commercially
available enzyme-linked immunosorbent assay (ELISA) that
selectively detects human I-FABP (HyCult Biotechnology,
Uden, The Netherlands). The ELISA will be performed
following the supplier’s protocol. I-FABP levels in urine
will be adjusted to urinary creatinine levels.
Claudin-3 levels will serve as secondary outcome meas-
ure. Urinary levels of Claudin-3 will be analyzed in dupli-
cate either by ELISA (if available at time of analysis) or by
Western blotting. Claudin-3 levels in urine will be adjusted
to urinary creatinine levels. If analyzed from Western blots,
equal amounts of each sample (adjusted to urinary creatin-
ine levels) will be separated by sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE), transferred
to a polyvinylidene fluoride (PVDF) membrane and probed
using primary antibody to Claudin-3 (Rabbit anti-claudin-3
(34–1700), Zymed Laboratories, San Francisco, CA). After
incubation with goat anti rabbit HRP-conjugated second-
ary antibody (Jackson, West Grove, PA), a signal will be
detected by supersignal west pico chemiluminescence sub-
strate (Pierce, Etten-Leur, the Netherlands). Band intensities
for each sample will be semi-quantitatively analyzed using
Quantity One (Biorad, Hercules, CA). This is a straightfor-
ward approach for semi-quantitative assessment of protein
levels. Urinary creatinine levels in the collected samples
will be determined at the Clinical Chemistry department.
The occurrence of (increasing) organ dysfunction will
be based upon the SOFA score.
Baseline, disease and treatment-related data
In addition to the outcome variables mentioned above,
the following data will be collected:
Intrinsic variables (baseline data):
 Age
 Gender
 Weight
 Height
 Comorbidity
Disease-related variables at admission:
 Reason of admission to the ICU (i.e., type of disease
or injury and type of intervention)
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fluoride tube)
 IAP level at baseline
 Urinary creatinine level at baseline (sediment tube)
 Acute Physiology and Chronic Health Evaluation II
(APACHE II) score at baseline; this is a validated
and commonly applied severity of disease classification
system [24]. An integer score ranging from 0 to 71 is
computed based upon 12 routine physiological
measurements with a higher scores implying a more
severe disease and a higher risk of death.
 Acute Physiology and Chronic Health Evaluation IV
(APACHE IV) score at baseline; this standardized
scoring metrics was developed in 2005 as an
improved version of the APACHE II. The previously
used set of equations were re-evaluated and improved
where needed. The most important change involved
the new categorization of disease groups [25].
 Simplified Acute Physiology Score II (SAPS II) at
baseline; this score was designed to measure the
severity of disease for patients admitted to Intensive
care units aged 15 or more [26]. The SAPS II score
is calculated from 12 routine physiological
measurements during the first 24 hours of ICU
admission, information about previous health status
and some information obtained at admission. The
computed score has a range from 0 to 163 points
and a predicted mortality between 0% and 100%.
Higher scores imply a more severe disease and a
higher risk of death.
 Sequential Organ Failure Assessment (SOFA) score
at baseline; this score is a validated and commonly
used score to track a patient’s status during the stay
in an ICU. The SOFA score is a scoring system to
determine the extent of a person’s organ function or
rate of failure [27-31]. The score is based upon six
different scores, one each for the respiratory system
(i.e., PaO2/FiO2 ratio), the cardiovascular system
(i.e., mean arterial pressure and vasopressor
requirement), the hepatic system (i.e., bilirubin
level), the coagulation system (i.e., platelet count),
the renal system (i.e., creatinine level or urine
output), and the neurological system (i.e., Glasgow
Coma Score). For each of these systems, a maximum
of four points can be attributed. SOFA scores are
determined on a daily basis during ICU admission.
Treatment-related variables:
 Medication use
 Interventions performed (i.e., type and number of
interventions)
 Sequential Organ Failure Assessment (SOFA) score
on day 1 to 4 (or until ICU discharge or death). Length of stay in the ICU
 Mortality during ICU stay and during hospital stay
Sample size calculation
In order to reliably calculate correlation coefficients for
the association between IAP, I-FABP and Claudin-3 levels,
at least 75 patients with IAH are needed. Malbrain et al.
showed in a multicenter study that in a general ICU popu-
lation, the prevalence of IAH (i.e., IAP > 12 mmHg) and
ACS (i.e., IAP > 20 mmHg with concomitant new organ
dysfunction) was 32%, and 4%, respectively [23]. Since we
will only follow-up on patients with a minimum of two
IAH/ACS risk factors, the percentage of enrolled patients
that will develop IAH or ACS will be higher, and is likely
to exceed 40% (unpublished data). Therefore, enrolling a
total population of 200 patients will be sufficient to ascer-
tain availability of 80 patients with IAH.
This will also be sufficient to compare I-FABP levels in
patients with physiologic IAP levels with patients that
developed IAH with adequate statistical power. Based
upon data provided by Kanda et al. we expect that mean
I-FABP levels will be 20.0 ± 10.0 ng/mL (range 0–100
ng/mL) in patients without IAH [32]. In patients with
IAH, the I-FABP levels will be higher (≥20 ng/mL). An
overall population of 200 patients (consisting of 120
controls and 80 patients with IAH) will be sufficient to
detect a 0.5 SD increase to 30.0 ± 12.5 ng/mL in I-FABP
level in patients with IAH (two-sided test with an α level
of 0.05) with >90% statistical power.
Recruitment and consent
Upon identification of two IAH risk factors, treatment
should be initiated in compliance with international guide-
lines of the WSACS. This implies that the baseline IAP
measurement and the first urine sample may have been
collected prior to obtaining informed consent from the
patient or his/her legal representative. Eligible persons ad-
mitted to the ICU who are at risk for developing IAH will
be informed about the trial and asked for consent at the
ICU. If patients are unconscious or otherwise not able to
sign informed consent, their legal representative will be
informed about the trial and asked to sign informed con-
sent on behalf of the patient. Upon recovery the patient
will be asked to sign final consent. The patient and their
legal representative will receive information and a consent
form from the attending physician, the clinical investigator
or a research assistant. If a patient or his/her legal repre-
sentative decides not to sign informed consent, data and
samples collected for that patient will be disposed of, and
patients will be excluded from analysis.
Study procedures
In patient with ≥2 risk factors for IAH or ACS, the
intra-abdominal pressure will be measured using an
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described by Cheatham and Safcsak [33] will be applied
for measuring IAP. In the current study, 20 mL of sa-
line will be used in order to comply with the current
recommendations of the WSACS. For the IAP measure-
ment, a Foley catheter will be disconnected and a 3-way-
valve will be inserted to create a continuous connection to
a pressure transducer (DTXPlus™ PRESS PA, reference No
686496; Argon Critical Care Systems, Singapore). For
every single measurement the valve connecting the urin-
ary drainage bag is closed and 20 mL of saline is instilled.
The midaxillary line will be used as reference.
During the first 72 hours after enrolment, IAP meas-
urement will be repeated every six hours (Table 1). At
those time points (including baseline), the following
samples will be collected:
1) Urine samples for measurement of I-FABP, Claudin-3
and creatinine levels: A single fresh specimen of urine
will be collected from the urinary bladder catheter
that is already in situ. Samples will be kept on ice andTable 1 Schedule of enrolment, interventions, and
assessments
Study period
Enrolment* Measurement ** Close-out
TIMEPOINT <T0 T0 to T72 ICU
discharge
ENROLMENT:
Eligibility screen X
Informed Consent X
ASSESSMENTS:
Baseline variables X
Disease-related
variables
X
IAP measurement X
Blood sample X
Urine sample X
I-FABP measurement X
Claudin-3 measurement X
Creatinine measurement X
Treatment-related
variables
X
SOFA score X
Adverse events X X
Length of ICU stay X X
Mortality during ICU
stay
X X
Secondary interventions X X
*Patients are considered eligible as soon as two IAH risk factors are present.
This can either be at ICU admission or later on during ICU stay.
**Patients are followed until 72 hours or until discharge from the ICU,
whichever comes first. Measurements are performed every six hours.then frozen at −80°C in aliquots within two hours of
collection.
2) Blood samples for measurement of serum I-FABP
levels (NB: this only applies to patients enrolled at
Erasmus MC, Rotterdam, the Netherlands): A single
blood sample (10 mL) will be drawn from the arterial
line that is already in situ. Blood will be collected in
pre-chilled vacutainer containing EDTA as
anticoagulent (BD Vacutainer, Becton Dickinson
Diagnostics, Aalst, Belgium) and kept on ice.
Blood will be centrifuged at 4°C, 4000× g for 15
minutes. Serum will be stored in aliquots at −80°C
within 2 hours until analysis.
The reason for following up on patients during the
first 72 hours after enrollment is based upon our observa-
tion (unpublished data) that over 95% of patients that de-
teriorate clinically due to increased IAP will do so during
the 12–24 hours. In order not to miss any patients that
may deteriorate somewhat later (e.g., due to leak at the
surgical site), we have set the time frame at 72 hours.
In order to assess if levels of I-FABP or Claudine-3 can
be used as a prognostic marker for intestinal ischemia-
related morbidity it is necessary to also collect clinical data
of patients during their entire stay at the ICU. These data
will be extracted from the ICU patient data management
system (PDMS), where they are stored as part of clinical
routine. This will be done using the APACHE II, APACHE
IV, SAPS II and SOFA score, which will be collected rou-
tinely for any patient admitted to the ICU. Follow-up in
the ICU will include a daily physical examination, vital
signs monitoring, routine blood tests, and chest radio-
graphs or other ancillary tests as required. The attending
physicians will record complications and events as well as
any (secondary) intervention performed such as decom-
pression laparotomy.
Data collection
Most variables will be collected as part of standard of
care and are routinely recorded in electronic patients re-
cords. The intra-abdominal pressure will be measured
by the ward nurse and recorded in the PDMS system
and on case record forms (CRF). This CRF contains no
patient identifiers. Urine and serum samples will be col-
lected, processed and frozen at −80°C by the researchers
or a research nurse. I-FABP and Claudin-3 levels will be
measured by the researcher (SGS) and results will be re-
corded in the CRF. CRFs are stored and secured at the
hospital where the patient is included.
Data management
Research data will be stored in a database (SPSS), and
will be handled confidentially and anonymously. Re-
search data that can be traced to individual patients can
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are the members of the research team, members of the
health care inspection, and members of the Medical Ethics
Committee Erasmus MC. The handling of personal data
will be in compliance with the Dutch Data Protection Act
and the privacy regulation of the Erasmus MC.
Research data will be stored under a code number. Only
the code number will be used for study documentation,
progress reports and publications. The principal investiga-
tor and research assistant are the only persons with the in-
formation linking individual persons to study code
numbers. Patient data and materials will be stored for a
maximum of 15 years after the end of the study. Patients
need to consent with this, and if not, their materials will
be disposed of upon termination of the study.
Statistical analysis
Data will be analyzed at the end of the study using the
Statistical Package for the Social Sciences (SPSS) version
21 or higher (SPSS, Chicago, Ill., USA) and will be re-
ported following the STrengthening the Reporting of
OBservational studies in Epidemiology (STROBE) guide-
lines. No interim analysis will be done. Normality of
continuous data will be assessed by the Shapiro Wilk
tests and by inspecting the frequency distributions (his-
tograms). Homogeneity of variances will be tested using
the Levene’s test.
Descriptive analysis will be performed in order to report
baseline characteristics (intrinsic variables and disease-
related variables) and outcome measures of the entire co-
hort as well as for the group of patients that develop IAH
(IAH group; IAP of 12 mmHg or higher on two separate
recordings) versus those that do not (control group). For
continuous data mean and SD (parametric data) or me-
dians and percentiles (non-parametric data) will be calcu-
lated and reported. For categorical data, numbers and
frequencies will be calculated and reported for the entire
cohort and for the IAH and the control group separately.
Univariate analysis will be performed in order to test the
difference in the primary and secondary outcome mea-
sures between the IAH group and the control group. Con-
tinuous data such as the I-FABP level (primary outcome)
of the Claudin-3 level (secondary outcome) will be tested
using a Student’s T-test (parametric data) or a Mann
Whitney U-test (non-parametric data). Chi-squared ana-
lysis will be used for statistical testing of categorical data
such as the number of secondary interventions. A p-value
<0.05 will be taken as threshold of statistical significance.
Depending upon the number of patients within the cohort
of the study that develop ACS and the mortality rate, simi-
lar tests will be used to compare data for those who devel-
oped ACS (or those who died) versus those who did not.
The patient cohort to be included will be heterogeneous
by nature, as IAH and ACS risk factors will differ betweenpatients. If it is possible to identify subgroups of patients
(e.g., liver transplant patients) subgroup analyses may be
performed. P-values <0.05 will be taken as threshold of
statistical significance.
The prognostic role of the I-FABP and Claudin-3 on
development of IAH, ACS, (increasing) organ dysfunc-
tion (based upon SOFA increase) or mortality will be
assessed. This analysis will be performed with Stata soft-
ware, version 10.0 or higher (StatCorp LP, College Sta-
tion, TX, USA), using the generalized linear latent and
mixed model (GLLAMM) framework. Herein, the binary
outcome IAH (or new organ dysfuncion or ACS or mor-
tality) will be used as dependent variable, and the level
of I-FABP or Claudin-3 will be included in the model as
time-dependent variable. Patient ID will be included as
clustering variable as up to 13 measurements per patient
will be available. Additional covariates such as age, gen-
der, number of IAH risk factors, and BM will be entered
into the model in order to evaluate their effect on the re-
lation between biomarker level and outcome. Random
intercept and slope will be considered. Results will be
expressed as Odds Ratios with their corresponding 95%
confidence interval and p-values.
Data monitoring
No data monitoring committee has been established as
this study is not an interventional study and all data are
either recorded in patient files (i.e., all clinical data in-
cluding baseline, disease-related and treatment-related
variables) as part of standard of care, or are generated
electronically (i.e., ELISA results and laboratory tests). A
random sample of at least 10% of all data will be double
checked by a member of the research team in order to
check the quality of the data entry into the database.
The only exception to this will be the primary outcome,
for which 100% of data will be checked.
Ethical considerations
The study will be conducted according to the principles
of the Declaration of Helsinki (64th World Medical Asso-
ciation General Assembly, Fortaleza, October 2013). This
study has been given a waiver by the medical research eth-
ics committee (MREC) Erasmus MC, University Medical
Center Rotterdam (Rotterdam, The Netherlands; reference
number MEC-2011-016) and by the local hospital board
in the participating center (Radboud University Medical
Center, Nijmegen, The Netherlands). Following review of
the protocol (version 1.0, dd December 13, 2010), the
MREC concluded that this study is not subject to the
Medical Research Involving Human Subjects Act (WMO,
in Dutch “Wet Medisch-wetenschappelijk Onderzoek met
mensen”). They concluded that the study is a medical/
scientific research, but no patients are subjected to
procedures or are required to follow rules of behavior.
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surance for subjects participating in medical research
(article 7, subsection 6 of the WMO and Medical Research
(Human Subjects) Compulsory Insurance Decree of 23
June 2003) was also waived. The reason for this dispensa-
tion is that participation in this study is without risks. Any
important protocol amendments will be submitted to the
MREC Erasmus MC before implementation.
Dissemination policy
Research data can be presented or publicized in agree-
ment with the clinical investigator and project leaders
only. No research data that can be traced to individual
persons will be presented or published.
Discussion
Every year, approximately 80,000 patients are admitted
to an ICU in the Netherlands [34]. Specific groups of
patients such as those who underwent major surgery
(e.g., vascular or intestinal surgery) or who sustained se-
vere trauma are at risk of developing morbidity and
mortality from postoperative or posttraumatic systemic
inflammatory response syndrome, sepsis and multiple
organ dysfunction. The development of such potentially
lethal complications in relatively healthy surgical or
trauma patients is poorly understood. Evidence is accumu-
lating that intra-abdominal hypertension plays a central
role in the origin of such postoperative and posttraumatic
sequelae. An increased intra-abdominal pressure level is
currently the best indicator of intra-abdominal complica-
tions. However, the IAP level does not always represent
the presence or absence of organ dysfunction, substantial
intra-abdominal damage may be present already prior to
the development of IAH and ACS. There is a distinctive
need for a non-invasive early-onset diagnostic test and
biomarkers. The main aim of the current study is to test if
urinary I-FABP or Claudine-3 levels can be used as diag-
nostic tool for identifying patients at risk for IAP-related
complications. This marker can then be used in order to
take the necessary clinical measures (e.g., decompressive
laparotomy) before the IAP has reached the level of irre-
versible damage to vital organs. This may prevent serious
morbidity or even death in a large group patients admitted
to the ICU.
Trial status
The study began enrolling patients on April 18, 2011.
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